STOCK TITAN

Belite Bio Inc - BLTE STOCK NEWS

Welcome to our dedicated news page for Belite Bio (Ticker: BLTE), a resource for investors and traders seeking the latest updates and insights on Belite Bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Belite Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Belite Bio's position in the market.

Rhea-AI Summary
Belite Bio, Inc (NASDAQ: BLTE) will host a webcast on November 14, 2023, to discuss financial results for Q3 2023 and provide a general business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
conferences earnings
-
Rhea-AI Summary
Belite Bio, Inc (NASDAQ: BLTE) presented final data from a 24-month Phase 2 study of Tinlarebant in adolescent STGD1 at the AAO Annual Meeting. The study showed that Tinlarebant was safe and well-tolerated, with a sustained lower DDAF lesion growth compared to ProgStar participants. 42% of Tinlarebant-treated subjects did not develop atrophic retinal lesions during the treatment period. Full enrollment of a two-year global Phase 3 study of Tinlarebant in childhood-onset STGD1 is complete.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
-
Rhea-AI Summary
Belite Bio, Inc (NASDAQ: BLTE) announced that the two-year data from the Phase 1b/2 trial of Tinlarebant in adolescent Stargardt Disease will be presented at the American Academy of Ophthalmology Annual Meeting. Tinlarebant has received Fast Track, Rare Pediatric Disease, and Orphan Drug Designations for STGD1.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.74%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.63%
Tags
conferences earnings
-
Rhea-AI Summary
Belite Bio has announced the dosing of the first subject in its Phase 3 trial for Tinlarebant, an orally administered tablet intended to slow disease progression in subjects with Stargardt Disease and Geographic Atrophy in advanced Dry Age-related Macular Degeneration. The trial plans to enroll approximately 430 subjects across multiple centers globally. Tinlarebant has the potential to be the first oral treatment for GA, as there are currently no approved oral or non-invasive treatments for the condition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.27%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.18%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.09%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.09%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
Belite Bio Inc

Nasdaq:BLTE

BLTE Rankings

BLTE Stock Data

1.07B
11.21M
60.29%
0.81%
0.13%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
San Diego

About BLTE

belite bio inc is a san diego based clinical stage biopharmaceutical drug development company targeting untreatable age-related metabolic diseases, including macular degeneration, liver disease and diabetes. developed from our anti-rbp4 technology platform, our lead candidate, lbs-008, is currently in a phase i clinical trial for dry age-related macular degeneration and its juvenile form, stargardt disease. lbs-008 has received orphan drug status in the us and europe, as well as rare pediatric disease status in the us.